IBio Net Income 2009-2021 | IBIO

IBio net income from 2009 to 2021. Net income can be defined as company's net profit or loss after all revenues, income items, and expenses have been accounted for.
IBio Annual Net Income
(Millions of US $)
2021 $-23
2020 $-38
2019 $-18
2018 $-16
2017 $-15
2016 $-10
2015 $-7
2014 $-4
2013 $-6
2012 $-6
2011 $-12
2010 $-6
2009 $-2
IBio Quarterly Net Income
(Millions of US $)
2021-06-30 $0
2021-03-31 $-8
2020-12-31 $-8
2020-09-30 $-8
2020-06-30 $-4
2020-03-31 $-5
2019-12-31 $-25
2019-09-30 $-5
2019-06-30 $-5
2019-03-31 $-4
2018-12-31 $-5
2018-09-30 $-4
2018-06-30 $-4
2018-03-31 $-4
2017-12-31 $-4
2017-09-30 $-4
2017-06-30 $-4
2017-03-31 $-4
2016-12-31 $-3
2016-09-30 $-3
2016-06-30 $-3
2016-03-31 $-3
2015-12-31 $-2
2015-09-30 $-2
2015-06-30 $-2
2015-03-31 $-2
2014-12-31 $-2
2014-09-30 $-1
2014-06-30 $-1
2014-03-31 $-1
2013-12-31 $-2
2013-09-30 $0
2013-06-30 $-1
2013-03-31 $-2
2012-12-31 $-1
2012-09-30 $-2
2012-06-30 $-1
2012-03-31 $-3
2011-12-31 $-2
2011-09-30 $0
2011-06-30 $-2
2011-03-31 $-3
2010-12-31 $-5
2010-09-30 $-3
2010-06-30 $-3
2010-03-31 $-2
2009-12-31 $-0
2009-09-30 $-2
2009-06-30 $-0
2009-03-31 $-0
2008-12-31 $-1
2008-09-30 $-1
Sector Industry Market Cap Revenue
Medical Medical - Biomedical and Genetics $0.190B $0.002B
Ibio Inc., formerly known as iBioPharma Inc., is a biopharmaceutical company that primarily focuses on developing vaccines and therapeutic proteins based upon its plant-based iBioLaunch platform technology. The Company's hydroponically grown green plants can be used for the development and manufacture of proteins applicable to a range of disease agents, such as influenza, sleeping sickness, anthrax, plague, human papillomavirus and veterinary influenza applications. IBio, Inc. is headquartered in Newark, Delaware.
Stock Name Country Market Cap PE Ratio
Bristol Myers Squibb (BMY) United States $126.527B 8.42
Bio-Rad Laboratories (BIO.B) United States $21.730B 46.31
QIAGEN (QGEN) Netherlands $11.880B 20.12
Biohaven Pharmaceutical Holding (BHVN) United States $8.436B 0.00
Emergent Biosolutions (EBS) United States $2.707B 6.53
Arcus Biosciences (RCUS) United States $2.445B 0.00
Myovant Sciences (MYOV) United Kingdom $1.866B 0.00
ADC Therapeutics SA (ADCT) Switzerland $1.750B 0.00
Zymeworks (ZYME) Canada $1.118B 0.00
Ambrx Biopharma (AMAM) United States $0.483B 0.00
SQZ Biotechnologies (SQZ) United States $0.326B 0.00
Enzo Biochem (ENZ) United States $0.160B 15.76